Rankings
▼
Calendar
EVMN FY 2023 Earnings — Evommune, Inc. Revenue & Financial Results | Market Cap Arena
EVMN
Evommune, Inc.
$319M
FY 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$5M
Gross Profit
$4M
80.0% margin
Operating Income
-$38M
-757.0% margin
Net Income
-$34M
-681.1% margin
EPS (Diluted)
$-1.13
Cash Flow
Operating Cash Flow
-$30M
Free Cash Flow
-$30M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$82M
Total Liabilities
$160M
Stockholders' Equity
-$78M
Cash & Equivalents
$29M
← Q1 2024
All Quarters